The Likelihood Of Breast Cancer Development In BRCA Women Beyond Age 60
The question remains whether the risk of breast cancer in BRCA1/BRCA2 mutation carriers beyond age 60 is enough to justify intensive screening or prophylactic surgery. …
Dr. Alan Stolier, MD, FACS, clinical breast oncologist, shares his expert medical perspective with a series of educational and scientific articles.
The question remains whether the risk of breast cancer in BRCA1/BRCA2 mutation carriers beyond age 60 is enough to justify intensive screening or prophylactic surgery. …
After a woman has developed an initial primary breast cancer, the risk of a second breast cancer takes on greater importance as it relates to surveillance and having the potential to impact the initial primary surgical approach. …
Most genetic testing and preventive measures are carried out in women less than 50 years. A multinational, multi-institutional group of scientists studied BRCA1 and BRCA2-positive patients from ages 50 to 75 to estimate the cumulative risk of all cancers. …
Current guidelines recommend only clinician visits to detect breast cancer recurrence following initial treatment. Imaging is only recommended for those patients demonstrating signs or symptoms of recurrence….
Current guidelines recommend only clinician visits to detect breast cancer recurrence following initial treatment. Imaging is only recommended for those patients demonstrating signs or symptoms of recurrence….
Antibody-drug conjugates (ADCs) are rapidly becoming one of the more important therapeutics in targeted cancer treatment. …
TP53 mutations were associated with aggressive histologic features that included high nuclear and histologic grade as well as high Ki67….
Most breast cancers are estrogen receptor-positive (ER+), approximately 70-80%. There is little doubt that HOT FLASHES are the most common adverse effect….
Arguments have persisted for many years regarding the safety of using hormone replacement during or after the treatment for early-stage (stage I or II) breast cancer. …
Researchers suggest that there may be some important and meaningful clinical activity using a new class of drugs and ER-low cancers….